Keywords: Novartis, Gilenia, Fingolimod, Merck KGaA, Cladribine, Multiple sclerosis

Novartis’ MS drug Gilenia cuts relapse rates, moving it forward in race with Merck KGaA’s cladribine

Article | 13 April 2010

Print This

Swiss drug major Novartis has presented positive new data for its multiple sclerosis drug Gilenia (fingolimod; FTY720) at the American ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in